ImmuPharma focuses on developing pioneering and novel drugs in specialist therapeutic areas
ImmuPharma’s strategy and business model are different from many of its peers. We are a risk-averse company and our management team has extensive experience in senior positions in some of the world’s leading pharmaceutical companies. We focus on developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry.
Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.
Our market strategy is to license our assets to leading international corporations that are well-placed to further develop and/or commercialise our drugs. Our corporate deal with Cephalon Inc. in 2008, for the worldwide rights of our lead drug candidate for the treatment of Lupus, Lupuzor™ is one example of this strategy in action.
Our vision and values
We are an ethical organisation with the vision to develop novel drugs to treat serious medical conditions, delivering value to patients, medical professionals, healthcare payers and our shareholders.
We value innovation, creativity, integrity, fairness, competency, professionalism, and we have a passion for what we do.
Tim McCarthy, Chairman of ImmuPharma firmly committed to Lupuzor™ ahead of the start of the Managed Access Programme, as discussed with Proactive Investors on 18 September 2018
Our portfolio of ground-breaking drugs
Developing innovative drugs for serious medical conditions
ImmuPharma PLC is a pharmaceutical drug development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The Company is focusing on developing innovative and novel medicines with high sales potential in specialist markets with serious unmet need.
ImmuPharma is focused on three therapeutic disease areas – Auto-immune (P140) | Oncology/Ophthalmology | Metabolism/Diabetes. Lupuzor™ is the Company’s most advanced drug candidate and is a treatment for Lupus, a life threatening auto immune-disease. Lupuzor™ received ‘Gold Standard’ approval from the US FDA for its Phase III trial with a Special Protocol Assessment and “Fast Track” designation.
Lupuzor ™ has now completed its Phase III pivotal trial. Top line results from the trial were announced in April 2018 (Click here) and May 2018 (Click here). ImmuPharma is led by a commercially focused Board and management team with extensive industry experience.
LupuzorTM a potential treatment for Lupus sufferers worldwide
Lupus is a chronic inflammatory disease which is thought to affect some 5 million people worldwide. Existing treatments offer marginal efficacy while leading to significant side-effects.
Lupuzor™ – a potential treatment for Lupus – received Fast-Track and Special Protocol Assessment designations from the US Food and Drug Administration.
ImmuPharma is now embarking on a Managed Access Programme for Lupuzor™, as confirmed in the Company’s Corporate Update in September 2018 - Click here.
Lupuzor™, is also known by its chemical name ‘Forigerimod’ or P140. ImmuPharma in conjunction with the CNRS, its collaboration partner, is exploring other opportunities around Lupuzor™’s mechanism of action and its applicability through its P140 platform to expand into other autoimmune conditions.
Oncology & Ophthalmology
ImmuPharma’s second most advanced pipeline programme, IPP-204106, is a potential treatment for various cancers and acts by modulating angiogenesis and proliferation. The programme involves the development of synthetic peptides, Nucants, which target nucleolin with very high affinity and selectivity. Nucleolin is a protein which controls critical pathways within the cell. The protein is over-expressed at the surface of dividing cells which makes its binding with Nucants very attractive because of its potential selectivity—this is of particular importance in tumour targeting. We are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications.
Metabolism and diabetes
ImmuPharma’s subsidiary ‘Ureka’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB). Jointly, ImmuPharma and CNRS have filed a new co-owned patent controlling this breakthrough peptide technology. The first therapeutic area being targeted is diabetes with glucagon-like peptide -1 agonists, a class of drugs for the potential treatment of diabetes, as well as initiating the development of novel peptides as glucagon antagonists – one of the novel approaches to treat Type I and Type II diabetes.
U.K, France & Switzerland.
Tim McCarthy FCCA, MBA
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera and Sygnis AG. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.
Dr Robert Zimmer MD, PhD
President & Chief Science Officer
Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.
Dimitri F Dimitriou MSc
Chief Executive Officer & Co-Founder
Mr Dimitriou has 30 years’ experience in the pharmaceutical and biotech industry. He is a co-founder and CEO of ImmuPharma PLC, a pharmaceutical company listed on AIM of the London Stock Exchange since 2006. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis in 1987. He has 2 degrees from the University of London - a Bachelor’s in biochemistry from Kings College and a Master’s in pathology and toxicology from Imperial College Medical School.
Dr Franco Di Muzio
Senior Non-Executive Director
Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000.
Dr Stéphane Méry
Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he was Partner at Beringea LLP, a $400m US/UK venture capital fund, where he was responsible for healthcare investments in Europe. Previously, he was the Fund Manager/CEO of the Bloomsbury Bioseed Fund, a Biotech and Medtech investment fund, which was behind the birth of successful companies such as Spirogen (sold to MedImmune), Abzema (listed on AIM), and Canbex, (recently sold to Ipsen). Prior to this, Stéphane was Associate Director, Worldwide Business Development, for SmithKline Beecham (GSK) where he was responsible for the negotiation of several major in-license deals and acquisitions. Before GSK, he was involved in the start-up of Double Helix Development, a successful strategic consultancy company specialising in R&D for the biotech and healthcare industry and recently sold to McCann. Just before, he worked as a management consultant at the American consultancy firm, ZS Associates, specialising on sales and marketing within the pharmaceutical industry. Stéphane is a Doctor in Veterinary Medicine, a trained Veterinary Pathologist, specialising in Nasal Toxicology at the Chemical Industry Institute of Toxicology (CIIT) in North Carolina, and holds an MBA from INSEAD (Fontainebleau).
Vice President, Operations & Finance
Ms Weimar has spent over 8 years at GlaxoSmithKline and her most recent position there was Director, Worldwide Business Development where she was involved in a number of corporate licensing deals. She has also held a number of positions in health economics, strategy development, sales and marketing.
Ms Weimar was been a non-executive director for the Avon and Wiltshire Mental Health Partnership NHS Trust responsible for ensuring the Trust was accountable to the public for the services it provided and for the public funds it used. She was a member of both the Audit and Remuneration Committees of the Trust.
Prior to joining GlaxoSmithKline, Ms Weimar spent 5 years at Arthur Andersen in San Francisco and London, responsible for a range of consulting and compliance projects.
Ms Weimar holds an MBA from London Business School and a BA in Economics from the University of California, Berkeley.
Head of Investor Relations
Lisa Baderoon has spent over 20 years working within the City of London and has been involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their media and investor relations strategies. During this time she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPO’s) and mergers and acquisitions both in the UK and internationally.
Until December 2011 she was a Partner at Buchanan Communications, one of the leading City financial public relations agencies, where she was instrumental in establishing its successful healthcare franchise. Her client responsibilities included developing impactful IR strategies in addition to excellence in message development and managing relationships with media, the investment community and sell side analysts in Europe. She also has significant issue and crisis management experience from both an investor and media perspective.
Over the last six years she has been advising ImmuPharma as a client on its media and investor relations strategy and in February 2012 was appointed Head of Investor Relations at the Company. Lisa has also recently founded Just B Communications, a consultancy which specialises in helping businesses develop effective communications and through her network of blue-chip London City contacts providing access to a number of sources of corporate and investor development opportunities.
London SW1H 0RG
Tel: +44 20 7152 4080
Fax: +44 20 7152 4001
ImmuPharma France S.A.
5, rue du Rhône
6060 Sarnen OW
Nominated Adviser ‘NOMAD”
SPARK Advisory Partners Limited
5 St John’s Ln, Clerkenwell, London EC1M 4BH
Tel +44 20 3368 3550
Stanford Capital Partners Limited
15-17 Eldon Street, London EC2M 7LD
Tel +44 203 815 8880
Si Capital Limited
43 Brook Street, Mayfair, London W1K 4HJ
Tel +44 203 841 6178
Bircham Dyson Bell, 50 Broadway, London SW1H 0BL, UK
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK